Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-05-16

Clinical Trial Update: Soy Isoflavones and Breast Cancer Risk Reduction [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating whether soy isoflavones can reduce breast cancer risk has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Soy Isoflavones (isoflavones from soy)

Snippet

Sponsor: The University of Texas Medical Branch, Galveston | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-05-16